Starling Oncology (STLN) Stock Overview
An oncology company, provides various oncology services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
STLN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Starling Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.24 |
| 52 Week High | US$6.67 |
| 52 Week Low | US$2.32 |
| Beta | 0.42 |
| 1 Month Change | -0.85% |
| 3 Month Change | 37.76% |
| 1 Year Change | 32.20% |
| 3 Year Change | 418.32% |
| 5 Year Change | -47.33% |
| Change since IPO | -46.03% |
Recent News & Updates
TOI: Index Additions And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their fair value estimate for Oncology Institute from $8.00 to $10.00, citing revised assumptions for revenue growth, profit margins, the discount rate, and a substantially higher future P/E multiple in their updated price target analysis. What’s in the News for Oncology Institute Oncology Institute was added to the Russell Small Cap Comp Value Benchmark, according to index constituent updates.
TOI: Index Additions And 2026 Guidance Will Support Future Upside Potential
Analysts have raised their fair value estimate for Oncology Institute from $5.00 to $7.00, citing updated assumptions for revenue growth, profit margins, a higher future P/E multiple, and a slightly higher discount rate. What's in the News Oncology Institute was added to the Russell Microcap Value Benchmark Index, according to index constituent change data.
TOI: Reaffirmed 2026 Revenue Outlook Will Support Higher Forward Earnings Power
Analysts have raised their price target for Oncology Institute to $7.75 from $7.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Oncology Institute Oncology Institute reaffirmed earnings guidance for fiscal 2026, keeping anticipated total revenue in the range of $630 million to $650 million.Recent updates
TOI: Index Additions And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their fair value estimate for Oncology Institute from $8.00 to $10.00, citing revised assumptions for revenue growth, profit margins, the discount rate, and a substantially higher future P/E multiple in their updated price target analysis. What’s in the News for Oncology Institute Oncology Institute was added to the Russell Small Cap Comp Value Benchmark, according to index constituent updates.TOI: Index Additions And 2026 Guidance Will Support Future Upside Potential
Analysts have raised their fair value estimate for Oncology Institute from $5.00 to $7.00, citing updated assumptions for revenue growth, profit margins, a higher future P/E multiple, and a slightly higher discount rate. What's in the News Oncology Institute was added to the Russell Microcap Value Benchmark Index, according to index constituent change data.TOI: Reaffirmed 2026 Revenue Outlook Will Support Higher Forward Earnings Power
Analysts have raised their price target for Oncology Institute to $7.75 from $7.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Oncology Institute Oncology Institute reaffirmed earnings guidance for fiscal 2026, keeping anticipated total revenue in the range of $630 million to $650 million.The Oncology Institute, Inc. (NASDAQ:TOI) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, The Oncology Institute, Inc. ( NASDAQ:TOI ) just kicked off its latest first-quarter results with...Investors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 26% Hiding
Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 26% in the...The Oncology Institute: Making Progress
Summary The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point. An analysis of The Oncology Institute follows in the paragraphs below. Read the full article on Seeking AlphaInvestors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 29% Hiding
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders won't be pleased to see that the share price has had a very...Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 26% Lower
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 26% in the last month, reversing a fair...The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 30% gain in the last...Value Based Care Contracts Will Unlock Future Oncology Demand
New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 161% gain in the last...Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 28% in the last month, reversing a fair...The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders would be excited to see that the share price has had a great...A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders are no doubt pleased to see that the share price has bounced...The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 29% in the...Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have had a horrible month, losing 28% after a relatively good period...Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Shareholder Returns
| STLN | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 5.8% | -3.0% | 2.4% |
| 1Y | 32.2% | 43.5% | 19.6% |
Return vs Industry: STLN underperformed the US Healthcare industry which returned 43.5% over the past year.
Return vs Market: STLN exceeded the US Market which returned 19.6% over the past year.
Price Volatility
| STLN volatility | |
|---|---|
| STLN Average Weekly Movement | 9.4% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STLN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STLN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 641 | Dan Virnich | starlingoncology.com |
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.
Starling Oncology, Inc. Fundamentals Summary
| STLN fundamental statistics | |
|---|---|
| Market cap | US$512.91m |
| Earnings (TTM) | -US$36.32m |
| Revenue (TTM) | US$545.76m |
Is STLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STLN income statement (TTM) | |
|---|---|
| Revenue | US$545.76m |
| Cost of Revenue | US$463.26m |
| Gross Profit | US$82.50m |
| Other Expenses | US$118.83m |
| Earnings | -US$36.32m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 15.12% |
| Net Profit Margin | -6.66% |
| Debt/Equity Ratio | -482.7% |
How did STLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 22:52 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Starling Oncology, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| David Larsen | BTIG |
| Alexander Draper | Guggenheim Securities, LLC |